Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 11/20 | 0.48 |
| ▸ | KDR | P35968 | 10/20 | 0.48 |
| ▸ | SRC | P12931 | 3/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | FLT1 | P17948 | 2/20 | 0.39 |
| ▸ | MST1R | Q04912 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL306763 | 0.84 | MET (0.54) | METKDRSRCMCHR1MST1R | |
| SCHEMBL307041 | 0.81 | MET (0.52) | METKDRSRCMCHR1MST1R | |
| SCHEMBL5585841 | 0.79 | MST1R (0.45) | METKDRSRCLTA4HFLT1 | |
| SCHEMBL18516386 | 0.78 | MET (0.63) | METKDR | |
| SCHEMBL13166733 | 0.77 | KDR (0.52) | METKDRSRCEGFRFLT1 | |
| SCHEMBL2283178 | 0.77 | MET (0.63) | METKDRSRCMST1R | |
| SCHEMBL13169019 | 0.76 | MET (0.67) | METKDRSRCMST1R | |
| SCHEMBL13185401 | 0.76 | KDR (0.51) | METKDRSRCEGFRFLT1 | |
| SCHEMBL13185371 | 0.75 | MCHR1 (0.56) | SRCMCHR1EGFRFLT1 | |
| SCHEMBL3617148 | 0.74 | MET (0.60) | METKDRMST1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | HGF, MET, FLT1 | MET 2/4885KDR 4/4885SRC 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.